OTC:BDTB
Bodhi Tree Biotechnology Inc
An OTC-listed biotechnology company currently operating at a loss with minimal revenue and a strained cash position.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock only if there are undisclosed breakthrough clinical data or a major strategic acquisition pending that could instantly revalue the company's pipeline assets. The minimal liability structure and low debt burden provide a unique opportunity for deep-value investors willing to take extreme risks on potential turnaround scenarios.
Bear Case
Avoid this stock due to the critical lack of cash runway with less than $110k remaining against a negative operating cash flow exceeding $150k per year. The company has generated zero revenue in the most recent period and is burning through its equity base rapidly without any clear path to profitability.
About Bodhi Tree Biotechnology Inc
Bodhi Tree Biotechnology Inc. is an OTC-traded biotechnology firm focused on developing innovative medical solutions, though current financials show minimal revenue generation in the most recent reporting period. The company operates with a lean capital structure but faces significant operational challenges including substantial net losses and limited cash reserves. Its primary activity centers on research and development efforts typical of early-stage biotech entities seeking to bring new therapeutics or diagnostic tools to market.
Analysis
Management Discussion
The company reported a net loss of $149,666 for the latest period, driven primarily by general and administrative expenses totaling $164,618 against only $17,000 in gross profit. Cash position deteriorated significantly from a beginning balance of $259,570 to an ending balance of $109,404, resulting in a negative net change in cash of -$150,166. The firm has exhausted its current working capital and retains no liabilities but faces an immediate deficit in retained earnings.
Industry Overview
The biotechnology industry offers high reward potential but is characterized by extreme volatility, long development cycles, and a binary outcome where failed trials wipe out investor capital. Companies like Bodhi Tree typically require substantial venture capital or public market funding to survive the research phase before generating meaningful commercial revenue.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2025 |
|---|---|
| Revenue | $17.0K |
| Cost of Revenue | $0 |
| Gross Profit | $17.0K |
| Operating Expenses | $164.6K |
| Operating Income | $-147.6K |
| G&A | $164.6K |
| Other OpEx | $0 |
| Non-Operating Income | $2 |
| Pre-Tax Income | $-147.6K |
| Income Tax | $2.0K |
| Continuing Ops | $-149.7K |
| Discontinued Ops | $0 |
| Net Income | $-149.7K |
| Minority Interest | $0 |
| Net to Common | $-149.7K |
| Metric | 2025 |
|---|---|
| Total Assets | $119.2K |
| Total Liabilities | $0 |
| Shareholders' Equity | $119.2K |
| Paid-In Capital | $328.2K |
| Retained Earnings | $-211.6K |
| Total L&E | $119.2K |
| Metric | 2025 |
|---|---|
| Net Income (CFO) | $-149.7K |
| Non-Cash Adjustments | $0 |
| Working Capital Changes | $-500 |
| Cash from Operations | $-150.2K |
| FX Effect | $0 |
| Net Change in Cash | $-150.2K |
| Beginning Cash | $259.6K |
| Ending Cash | $109.4K |
Frequently Asked Questions
How does Bodhi Tree Biotechnology Inc make money?
Research and Development, Strategic Partnerships and Licensing, and Potential Clinical Trial Operations
What are the main risks for BDTB?
Severe liquidity crisis with cash reserves dwindling to under $110k and annual operational burn of approximately $150k, consistent history of net losses exceeding $149k annually, lack of diversified revenue streams with negligible current sales, and high probability of delisting or requiring immediate equity dilution.
What is BDTB's competitive advantage?
Specialized scientific expertise in niche therapeutic areas, potential for high-value patent protection on future discoveries, and a low-burn capital structure that allows flexibility if new funding rounds are secured.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.